Vor Biopharma (VOR) Stock Fundamentals, Analysis & Risk Signals

Health score, price, valuation, risk signals, and key metrics at a glance.

Vor Biopharma

NasdaqGS•Healthcare•Biotechnology

$19.84-1.07(-0.05%)Market open

Market Cap

$1.15B

P/E

0.8x

Vor Biopharma Inc., a clinical-stage biopharmaceutical company, focuses on the development of a novel therapy in the treatment of autoimmune diseases. The company offers telitacicept, a novel fusion protein for the treatment of generalized myasthenia gravis, systemic lupus erythematosus, and rheumatoid arthritis, as well as Sjögren's disease and IgA nephrapathy. It has a license agreement with RemeGen Co., Ltd. for the exploitation, development, and commercialization of telitacicpet and related products. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.

How this company scores

WeakMetricSide Score: 40/100

Grade capped at D — Negative equity — the balance sheet is insolvent. Strongest: Growth (15/25); weakest: Cash & Earnings Quality (4/25).

Profitability6/25

Growth15/25

Balance Sheet & Red Flags15/25

Cash & Earnings Quality4/25

Strengths

Rising earningsInterest easily coveredProfit converts from growthNet cash position

Grade capped at D

Negative equity — the balance sheet is insolvent.

Valuation vs. 5-year range

Today's multiple positioned against its own trailing range — a visual premium/discount check.

P/E · 0.8x5y range 0.8x – 1.6x

P/B · 27.1x5y range 13.1x – 36.8x

Currently above its 14-quarter median.

Watch items

Data-driven signals worth keeping an eye on across the last 8 quarters

High Risk

Margin Pressure

Red Flag

The company posted negative operating margins in recent quarters — core operations are unprofitable.

Earnings Quality

Red Flag

Free cash flow has been negative in 8 of the last 8 quarters — earnings are not translating to cash.

Price & Volume

Market Cap $1.15B

Metrics at a Glance

as of September 2026

Revenue & Profit

Revenue, EBITDA, operating income, net income, EPS, and shares

TTM Revenue: $0
Q. Revenue: $0
TTM EBITDA: $-177.35M
TTM Op. Income: $-177.42M
Q. Op. Income: $-58.44M
TTM Net Income: $1.35B
Q. Net Income: $-86.73M
EPS: $-1.45
Shares Out.: $59.67M

$0 in TTM revenue was flat at zero YoY, reaching $0 last quarter. TTM EBITDA of $-177.35M and TTM operating income of $-177.42M show growth is flowing through to the bottom line. TTM net income of $1.35B means revenue is converting into profit.

Margins

Gross, EBITDA, operating, and net margin trends

EBITDA Margin: N/A
Op. Margin: -5844400000.0%
Net Margin: -8672700000.0%

Op. margin of -5844400000.0% is down 3033700000.0% YoY — costs are rising relative to revenue. Net margin at -8672700000.0% Across the last 8 quarters, operating margin has fallen for 2 consecutive quarters — a weakening trend.

Price Ratios

P/E, P/S, P/B, EV/EBITDA, FCF yield, and earnings yield

P/E Ratio: 0.8x
P/S Ratio: N/A
P/B Ratio: N/A

At 0.8x P/E, the stock trades below typical market levels. P/S of 0.0x and P/B of 0.0x provide additional context. Use the growth and margin sections to judge whether the multiple is justified. Over the past year, P/E is up 0% — an improving trend.

Assets & Liabilities

Total assets, cash, debt, book value, and leverage

Total Assets: $496.31M
Cash: $78.98M
Long-Term Debt: N/A
Book Value: $-137.17M
D/E Ratio: N/A
Debt/EBITDA: N/A

Cash Flow

Operating cash flow, free cash flow, FCF margin, and earnings quality

Op. Cash Flow: $-32.75M
TTM Free Cash Flow: $-119.68M
FCF Margin: N/A
FCF / Net Income: -0.1

TTM FCF of $-119.68M on $-32.75M in operating cash flow. The FCF / Net Income ratio of -0.1x means the business consumes cash — it is not yet self-funding. Across the last 8 quarters, free cash flow has risen for 2 consecutive quarters — an improving trend.